Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bremelanotide for HSDD in premenopausal women
NCT02333071Phase 3Completed
- Sponsor
- Palatin Technologies, Inc.
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hypoactive sexual desire disorder (HSDD) comparing Bremelanotide with Placebo (2 arms). Primary endpoints: Female Sexual Function Index (Question Q1 and Q2) at 52 weeks and Female Sexual Distress Scale-Desire/Arousal/Orgasm (Item 13) at 52 weeks. Started Dec 2014; status: completed.
02
Drugs
bremelanotide
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT02333071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333071.